First and only once-weekly patch for convenient, well-tolerated delivery of most used drug for the treatment of Alzheimer's-related dementia
Tislelizumab is now approved for seven indications in China
A total of 21 applicants have been approved for 49 products, with the potential to utilize an incentive amount of Rs. 2541 crore
The RI investment comes on the back of three other recently completed transactions in Malaysia and Singapore in the last two months
Transformative closed-loop technology senses the spinal cord's response to stimulation and instantaneously adjusts therapy to sustain durable, optimized treatment
Internationally accepted pharmaceutical GDP regulations stipulate that distributors of pharmaceutical products and warehouses must align their operations with the specified standards
Women's health is in fact a direct reflection of the nation's overall health
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Company expects strong organic growth in sales, EBITDA in 2022
Subscribe To Our Newsletter & Stay Updated
